Dr. Javier Alcover is a distinguished Spanish biomedical researcher and Director of the Laboratorio de Aplicaciones at Diater (Spain), where he has been serving since 2000. His research primarily focuses on immunotherapy, allergology, and infectious disease prevention, emphasizing the development of innovative therapeutic approaches that integrate clinical and molecular insights. Over the years, Dr. Alcover has contributed extensively to translational research aimed at improving patient outcomes through safer and more effective immunological treatments. His 2023 study in Vaccines provided real-world clinical evidence on the safety and efficacy of an enhanced allergen-specific immunotherapy for bee venom allergy, underscoring his expertise in clinical immunology. His earlier works, such as the Urologia Internationalis (2019) publication, examined bacterial immune prophylaxis in preventing recurrent urinary tract infections, while his Future Microbiology (2017) study highlighted the antimicrobial potential of natural compounds like xyloglucan, hibiscus, and propolis. In Dermatology and Therapy (2018), Dr. Alcover explored novel nonsteroidal formulations targeting inflammatory and pruritic mediators in allergic contact dermatitis, demonstrating his commitment to advancing topical immunotherapies. His work in Allergy, Asthma & Immunology Research (2016) contributed to the understanding of orthologous allergens and the diagnostic relevance of the major allergen Alt a 1, reflecting his impact on diagnostic innovation. Furthermore, his involvement in hepatitis C virus antibody detection research, published in Transfusion (2016), showcases his broader contributions to infectious disease diagnostics. Dr. Alcover’s interdisciplinary research portfolio reflects a strong dedication to bridging laboratory innovation with clinical practice, advancing immune-based therapeutics, and enhancing diagnostic precision in allergy and infection-related diseases.
-
González Guzmán, L. A., García Robaina, J. C., Barrios Recio, J., Escudero Arias, E., Liñares Mata, T., Cervera Aznar, R., De La Roca Pinzón, F., Miguel Polo, L. del C., Arenas Villarroel, L., López Couso, V. P., et al., & Alcover, J. (2023). Real-world safety and efficacy clinical data of an improved allergen-specific immunotherapy product for the treatment of bee venom allergy. Vaccines, 11(5), 979.
-
López-Martín, L., Alcover-Díaz, J., Charry-Gónima, P., González-López, R., Rodríguez-Gil, D., Palacios-Peláez, R., & González-Enguita, C. (2019). Prospective observational cohort study of the efficacy of bacterial immune prophylaxis in the prevention of uncomplicated, recurrent urinary tract infections. Urologia Internationalis, 103(4), 456–462.*
-
Gordon, W. C., García López, V., Bhattacharjee, S., Rodríguez Gil, D., Alcover Díaz, J., Pineda de la Losa, F., Palacios Peláez, R., Tiana Ferrer, C., Bacchini, G. S., Jun, B., et al. (2018). A nonsteroidal novel formulation targeting inflammatory and pruritus-related mediators modulates experimental allergic contact dermatitis. Dermatology and Therapy, 8(1), 111–126.*
-
Fraile, B., Alcover, J., Royuela, M., Rodríguez, D., Chaves, C., Palacios, R., & Piqué, N. (2017). Xyloglucan, Hibiscus and Propolis for the prevention of urinary tract infections: Results of in vitro studies. Future Microbiology, 12(6), 533–541.*
-
Moreno, A., Pineda, F., Alcover, J., Rodríguez, D., Palacios, R., & Martínez-Naves, E. (2016). Orthologous allergens and diagnostic utility of major allergen Alt a 1. Allergy, Asthma & Immunology Research, 8(5), 428–437.*